Literature DB >> 31530268

Jingshu Keli and its Components Notoginsenoside R1 and Ginsenoside Rb1 Alleviate the Symptoms of Cervical Myelopathy through Kir3.1 Mediated Mechanisms.

Renjie Yan1, Rui Chen1, Jiahui Wang1, Jian Shi2, Wagner Ferreira Dos Santos3, Zhiru Xu1, Li Liu1,4.   

Abstract

BACKGROUND &
OBJECTIVE: Cervical Spondylotic Myelopathy (CSM) is one of the most serious spinal cord disorders in adults. Pharmacological modulation of ion channels is a common strategy to interfere with CSM and prevent neuronal damage.
METHODS: Here, we investigated the effects of Jingshu Keli (JSKL), a traditional Chinese herbal formula, on CSM-related gait abnormality, mechanical allodynia and thermal hyperalgesia, and assessed the neuronal mechanisms of JSKL on cultured brainstem cells. Behavioral tests and patch clamp recordings were performed to make this assessment.
RESULTS: In our study, we found that JSKL significantly recovered the gait performance (P<0.001) and decreased the levels of mechanical pain in 18.9% (P<0.01) and thermal pain in 18.1% (P<0.05). Further investigation suggested that JSKL and its containing ginsenoside Rb1 (GRb1), notoginsenoside R1 (NGR1) reduced the action potential frequency in 38.5%, 27.2%, 25.9%, and hyperpolarized resting membrane potential in 15.0%, 13.8%, 12.1%, respectively. Kir channels, not KV channels and KCa channels, were the major intermediate factors achieving treatment effects. Finally, immunostaining results showed that the phosphorylation of Kir3.1 was promoted, whereas the total expression level did not change.
CONCLUSION: Our study reveals a novel strategy of treating CSM by using Traditional Chinese Medicines (TCMs) containing active components. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Jingshu granule; Kir3.1; cervical spondylotic myelopathy; cultured brainstemzzm321990neurons; ginsenoside Rb1; notoginsenoside R1.

Mesh:

Substances:

Year:  2019        PMID: 31530268     DOI: 10.2174/0929866526666190911150514

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  1 in total

1.  A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy.

Authors:  Chongqing Xu; Xiaoning Zhou; Zhengyi Tong; Junming Ma; Jie Ye; Jinhai Xu; Wen Mo
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.